Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 22 Jan 2019 |
| Genmab Announces Initiation of U.S. FDA Regulatory Submission for Label Expansion of Daratumumab in Combination with Lenalidomide and Dexamethasone in Front Line Multiple Myeloma | 22 Jan 2019 |
| Major Shareholder Announcement | 17 Jan 2019 |
| Genmab Achieves USD 75 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen | 8 Jan 2019 |
| Genmab to Present at the 37th Annual J.P. Morgan Healthcare Conference | 3 Jan 2019 |